Jacobs Levy Equity Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Jacobs Levy Equity Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-33,968	Closed	-$121K	–	1036
2020 Q4	$121K	Sell	33,968 -8,000	-19%	-$32.2K	﹤0.01%	988
2020 Q3	$168K	Sell	41,968 -36,666	-47%	-$146K	﹤0.01%	975
2020 Q2	$214K	Buy	78,634 +58	+0.1%	+$171	﹤0.01%	940
2020 Q1	$166K	Buy	78,576 +2,580	+3%	+$10.5K	﹤0.01%	911
2019 Q4	$413K	Buy	75,996 +32,979	+77%	+$115K	﹤0.01%	809
2019 Q3	$129K	Sell	43,017 -16,701	-28%	-$70.1K	﹤0.01%	880
2019 Q2	$223K	Buy	+59,718	New	+$234K	﹤0.01%	864
2019 Q1	–	Sell	-56,174	Closed	-$206K	–	972
2018 Q4	$206K	Buy	56,174 +12,400	+28%	+$84.5K	﹤0.01%	873
2018 Q3	$376K	Buy	+43,774	New	+$438K	0.01%	830
2018 Q1	–	Sell	-14,026	Closed	-$145K	–	1011
2017 Q4	$145K	Buy	+14,026	New	+$180K	﹤0.01%	932

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Jacobs Levy Equity Management's CRVS Position: Q1 2021 in Review

Jacobs Levy Equity Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2021, closing a stake of 33,968 shares — an estimated $121K sold.

Jacobs Levy Equity Management first reported a position in CRVS in Q4 2017 and held it in 10 quarters. The position peaked at $413K in Q4 2019. 49 funds tracked by Wall St. Rank hold CRVS as of Q1 2021.

Jacobs Levy Equity Management reported no remaining Corvus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 33,968 Corvus Pharmaceuticals shares in Q1 2021, an estimated $121K.
Jacobs Levy Equity Management first reported a position in Corvus Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Jacobs Levy Equity Management's Corvus Pharmaceuticals position peaked at $413K in Q4 2019.
49 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2021, filed 17 May 2021.